JP2022180379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022180379A5 JP2022180379A5 JP2022134954A JP2022134954A JP2022180379A5 JP 2022180379 A5 JP2022180379 A5 JP 2022180379A5 JP 2022134954 A JP2022134954 A JP 2022134954A JP 2022134954 A JP2022134954 A JP 2022134954A JP 2022180379 A5 JP2022180379 A5 JP 2022180379A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- terminus
- protein
- light
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18176889.6 | 2018-06-09 | ||
| EP18176888 | 2018-06-09 | ||
| EP18176889 | 2018-06-09 | ||
| EP18176888.8 | 2018-06-09 | ||
| EP19159321 | 2019-02-26 | ||
| EP19159321.9 | 2019-02-26 | ||
| PCT/EP2019/064942 WO2019234220A1 (en) | 2018-06-09 | 2019-06-07 | Dll3-cd3 bispecific antibodies |
| JP2020568407A JP7133043B2 (ja) | 2018-06-09 | 2019-06-07 | Ｄｌｌ３－ｃｄ３二重特異性抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568407A Division JP7133043B2 (ja) | 2018-06-09 | 2019-06-07 | Ｄｌｌ３－ｃｄ３二重特異性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022180379A JP2022180379A (ja) | 2022-12-06 |
| JP2022180379A5 true JP2022180379A5 (https=) | 2023-04-24 |
Family
ID=66752128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568407A Active JP7133043B2 (ja) | 2018-06-09 | 2019-06-07 | Ｄｌｌ３－ｃｄ３二重特異性抗体 |
| JP2022134954A Pending JP2022180379A (ja) | 2018-06-09 | 2022-08-26 | Ｄｌｌ３－ｃｄ３二重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568407A Active JP7133043B2 (ja) | 2018-06-09 | 2019-06-07 | Ｄｌｌ３－ｃｄ３二重特異性抗体 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11332541B2 (https=) |
| EP (2) | EP3802598B1 (https=) |
| JP (2) | JP7133043B2 (https=) |
| KR (1) | KR20210018311A (https=) |
| CN (7) | CN112513092B (https=) |
| AU (1) | AU2019280900B2 (https=) |
| BR (1) | BR112020022898A2 (https=) |
| CA (1) | CA3099956A1 (https=) |
| CL (1) | CL2020003105A1 (https=) |
| CO (1) | CO2020015172A2 (https=) |
| CR (1) | CR20200601A (https=) |
| DK (1) | DK3802598T3 (https=) |
| EC (1) | ECSP20084864A (https=) |
| ES (1) | ES3021463T3 (https=) |
| FI (1) | FI3802598T3 (https=) |
| HR (1) | HRP20250443T1 (https=) |
| HU (1) | HUE071620T2 (https=) |
| IL (1) | IL279235A (https=) |
| JO (1) | JOP20200313A1 (https=) |
| LT (1) | LT3802598T (https=) |
| MA (1) | MA52742B1 (https=) |
| MX (1) | MX2020013348A (https=) |
| MY (1) | MY199655A (https=) |
| PE (1) | PE20210321A1 (https=) |
| PH (1) | PH12020552080A1 (https=) |
| PL (1) | PL3802598T3 (https=) |
| RS (1) | RS66693B1 (https=) |
| SA (1) | SA520420748B1 (https=) |
| SG (1) | SG11202011134XA (https=) |
| SI (1) | SI3802598T1 (https=) |
| TW (1) | TWI848953B (https=) |
| WO (1) | WO2019234220A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| CA3097193A1 (en) | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| US12509524B2 (en) | 2018-09-28 | 2025-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| WO2020086446A1 (en) * | 2018-10-22 | 2020-04-30 | International Aids Vaccine Initiative | Anti-hiv antibodies |
| TWI878355B (zh) * | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| US11976133B2 (en) * | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CR20220541A (es) * | 2020-03-31 | 2022-11-28 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| EP4153625A4 (en) * | 2020-05-20 | 2024-09-25 | The Trustees Of Columbia University In The City Of New York | STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE |
| CN111551733A (zh) * | 2020-05-29 | 2020-08-18 | 武汉大学 | 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| JP2023548590A (ja) * | 2020-11-06 | 2023-11-17 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 小細胞肺がんの分類と治療のための方法およびシステム |
| MX2023008285A (es) * | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo anti-dll3-farmaco. |
| CA3204628A1 (en) * | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| MX2023012614A (es) * | 2021-05-08 | 2023-11-03 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Molecula de union contra dll3 y uso de la misma. |
| IL307646A (en) * | 2021-05-10 | 2023-12-01 | Amgen Inc | Dosing regimen for combination therapy targeting DLL3 and PD-1 |
| KR20240050373A (ko) | 2021-09-02 | 2024-04-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 미래의 색값 또는 대응하는 특성을 결정하는 방법 및 이를 위한 장치 |
| CA3240378A1 (en) * | 2021-12-23 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody |
| AU2023217790A1 (en) * | 2022-02-10 | 2024-08-22 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Bispecific antigen-binding molecule and use thereof |
| KR20240153575A (ko) | 2022-02-23 | 2024-10-23 | 암젠 인크 | Dll3을 표적화하는 암 치료 |
| CN119256017A (zh) * | 2022-06-23 | 2025-01-03 | 江苏恒瑞医药股份有限公司 | 特异性结合dll3和cd3的抗原结合分子及其医药用途 |
| CA3266173A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| JP2026512969A (ja) | 2022-10-26 | 2026-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇを活性化することができる複素環式化合物 |
| WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2024123965A2 (en) * | 2022-12-08 | 2024-06-13 | Amgen Inc. | Methods for treating dll3-expressing cancer |
| US20240352102A1 (en) * | 2023-01-27 | 2024-10-24 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions for treating tauopathies and methods of use thereof |
| IL322887A (en) | 2023-02-27 | 2025-10-01 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof |
| EP4712977A1 (en) | 2023-05-19 | 2026-03-25 | Boehringer Ingelheim International GmbH | Uses of t cell engaging proteins in the treatment of cancer |
| WO2025131024A1 (zh) * | 2023-12-22 | 2025-06-26 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合dll3和cd3的双特异性抗体的药物组合物 |
| WO2025146127A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 针对dll3和cd3的双特异性抗体及其应用 |
| TW202600597A (zh) * | 2024-03-04 | 2026-01-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 靶向ｄｌｌ３之三特異性抗體構築體及其使用方法 |
| TW202602488A (zh) | 2024-03-11 | 2026-01-16 | 美商安進公司 | 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法 |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| WO2026059931A2 (en) * | 2024-09-11 | 2026-03-19 | Telix Targeting Technologies, Inc. | Dll3 antigen binding constructs |
| WO2026060304A1 (en) | 2024-09-13 | 2026-03-19 | Amgen Inc. | Subcutaneous administration of anti-dll3 agent for treatment of cancer |
| WO2026075950A1 (en) | 2024-10-01 | 2026-04-09 | Amgen Inc. | Dosing regimen for anti-dll3 agent |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| WO1992010209A1 (en) | 1990-12-04 | 1992-06-25 | The Wistar Institute Of Anatomy And Biology | Bifunctional antibodies and method of preparing same |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| JP4567436B2 (ja) | 2001-07-20 | 2010-10-20 | ライフ テクノロジーズ コーポレーション | 発光ナノ粒子およびそれらの調製方法 |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| WO2007010954A1 (en) | 2005-07-15 | 2007-01-25 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| EP1960552A2 (en) | 2005-12-16 | 2008-08-27 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| PE20120540A1 (es) | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SI2473617T1 (sl) | 2009-09-01 | 2020-07-31 | F. Hoffmann-La Roche Ag | Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A |
| KR101721187B1 (ko) | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
| DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| US8916162B2 (en) | 2010-02-20 | 2014-12-23 | Alexey Gennadievich Zdanovsky | Botulinum neurotoxin antigenic compositions and methods |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| IN2013MN01438A (https=) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| CN103796678B (zh) | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| RU2654567C2 (ru) | 2011-10-11 | 2018-05-21 | Дженентек, Инк. | Улучшенная сборка биспецифических антител |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| IN2015DN01299A (https=) | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| US20150016666A1 (en) | 2012-11-02 | 2015-01-15 | Google Inc. | Method and Apparatus for Determining Geolocation of Image Contents |
| JP6385357B2 (ja) | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| JP2016522168A (ja) | 2013-04-05 | 2016-07-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−４抗体及び二重特異性抗体及びその使用 |
| WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| BR122021009041B1 (pt) | 2014-05-06 | 2022-11-29 | Genentech, Inc | Métodos para a preparação de uma proteína heteromultimérica |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MX384418B (es) * | 2014-07-31 | 2025-03-14 | Amgen Res Munich Gmbh | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido. |
| GB201414823D0 (en) | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
| EA202193002A2 (ru) | 2014-09-03 | 2022-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23a и фно-альфа, и его применение |
| CA2960569A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-Laroche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
| JP2018519832A (ja) * | 2015-06-30 | 2018-07-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多重特異的結合タンパク質 |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| US20190002563A1 (en) | 2015-08-17 | 2019-01-03 | Macrogenics, Inc. | Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof |
| RS61510B1 (sr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| JP7314146B2 (ja) * | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| KR20260046525A (ko) * | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| KR102839606B1 (ko) | 2018-12-31 | 2025-07-29 | 삼성디스플레이 주식회사 | 색변환 기판 및 표시 장치 |
| US12084501B2 (en) * | 2021-03-24 | 2024-09-10 | Janssen Biotech, Inc. | Proteins comprising CD3 antigen binding domains and uses thereof |
-
2019
- 2019-06-06 TW TW108119701A patent/TWI848953B/zh active
- 2019-06-07 EP EP19728454.0A patent/EP3802598B1/en active Active
- 2019-06-07 WO PCT/EP2019/064942 patent/WO2019234220A1/en not_active Ceased
- 2019-06-07 PE PE2020001978A patent/PE20210321A1/es unknown
- 2019-06-07 SI SI201930914T patent/SI3802598T1/sl unknown
- 2019-06-07 KR KR1020207036859A patent/KR20210018311A/ko active Pending
- 2019-06-07 AU AU2019280900A patent/AU2019280900B2/en active Active
- 2019-06-07 CN CN201980051335.7A patent/CN112513092B/zh active Active
- 2019-06-07 MA MA52742A patent/MA52742B1/fr unknown
- 2019-06-07 MX MX2020013348A patent/MX2020013348A/es unknown
- 2019-06-07 CN CN202411429697.4A patent/CN119499365A/zh active Pending
- 2019-06-07 CN CN202411358798.7A patent/CN119490599A/zh active Pending
- 2019-06-07 ES ES19728454T patent/ES3021463T3/es active Active
- 2019-06-07 CN CN202411433636.5A patent/CN120131936A/zh active Pending
- 2019-06-07 HU HUE19728454A patent/HUE071620T2/hu unknown
- 2019-06-07 PL PL19728454.0T patent/PL3802598T3/pl unknown
- 2019-06-07 US US16/434,188 patent/US11332541B2/en active Active
- 2019-06-07 JP JP2020568407A patent/JP7133043B2/ja active Active
- 2019-06-07 JO JOP/2020/0313A patent/JOP20200313A1/ar unknown
- 2019-06-07 CN CN202411369181.5A patent/CN119529097A/zh active Pending
- 2019-06-07 MY MYPI2020006025A patent/MY199655A/en unknown
- 2019-06-07 LT LTEPPCT/EP2019/064942T patent/LT3802598T/lt unknown
- 2019-06-07 DK DK19728454.0T patent/DK3802598T3/da active
- 2019-06-07 FI FIEP19728454.0T patent/FI3802598T3/fi active
- 2019-06-07 CN CN202411404784.4A patent/CN119285788A/zh active Pending
- 2019-06-07 HR HRP20250443TT patent/HRP20250443T1/hr unknown
- 2019-06-07 CA CA3099956A patent/CA3099956A1/en active Pending
- 2019-06-07 BR BR112020022898-2A patent/BR112020022898A2/pt unknown
- 2019-06-07 SG SG11202011134XA patent/SG11202011134XA/en unknown
- 2019-06-07 RS RS20250344A patent/RS66693B1/sr unknown
- 2019-06-07 EP EP24222173.7A patent/EP4566621A3/en active Pending
- 2019-06-07 CN CN202411404799.0A patent/CN119241717A/zh active Pending
- 2019-06-07 CR CR20200601A patent/CR20200601A/es unknown
-
2020
- 2020-11-30 CL CL2020003105A patent/CL2020003105A1/es unknown
- 2020-12-02 CO CONC2020/0015172A patent/CO2020015172A2/es unknown
- 2020-12-03 PH PH12020552080A patent/PH12020552080A1/en unknown
- 2020-12-06 IL IL279235A patent/IL279235A/en unknown
- 2020-12-08 SA SA520420748A patent/SA520420748B1/ar unknown
- 2020-12-30 EC ECSENADI202084864A patent/ECSP20084864A/es unknown
-
2022
- 2022-03-04 US US17/686,453 patent/US12173083B2/en active Active
- 2022-08-26 JP JP2022134954A patent/JP2022180379A/ja active Pending
-
2023
- 2023-06-01 US US18/327,456 patent/US12528879B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180379A5 (https=) | ||
| JP2023540732A5 (https=) | ||
| JP2020114828A5 (https=) | ||
| NZ596865A (en) | Single-chain multivalent binding proteins with effector function | |
| Alfthan et al. | Properties of a single-chain antibody containing different linker peptides | |
| JP2019112445A5 (https=) | ||
| JP2024527293A5 (https=) | ||
| JP2019519227A5 (https=) | ||
| US5328985A (en) | Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system | |
| ES2563027T3 (es) | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| JP2017504577A5 (https=) | ||
| JP2023504172A5 (https=) | ||
| MX2023000504A (es) | Anticuerpos tetrahedricos. | |
| RU2011140509A (ru) | Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения | |
| JP2017504578A5 (https=) | ||
| ES2683847T3 (es) | Inmunoglobulina citotóxica | |
| JP2017512825A5 (https=) | ||
| CA2468583A1 (en) | Self-assembling multimeric binding complexes derived from ab5 toxin family members | |
| ATE199392T1 (de) | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung | |
| JP2017509594A5 (https=) | ||
| JP2017518748A5 (https=) | ||
| JP2014533239A5 (https=) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab |